The vaccine was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Health Ministry.
The third, post-registration, stage of clinical tests began on August 25. The vaccine was developed on a platform that had been used for a number of other vaccines.
According to the Russian Health Ministry, these vaccines have proved their ability to form lasting immunity for a period of up to two years.
The first batch of the vaccine was dispatched to Russian regions on September 12, said the TASS report.